Drugging the ‘undruggable’ cancer targets

By C. V. Dang, E. Reddy, Kevan M. Shokat, L. Soucek. Nature Reviews. Cancer, 2017

753 citations recorded by the source corpus.

The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/34f0384090c93270b336c5e0205077f86c71f19e

Citations in the corpus

• Empowering Biomedical Discovery with AI Agents (2024, neutral): “…work alongside human scientists to explore research questions that are challenging for the field, such as binder design for undruggable targets [115], significantly improving specificity and efficiency of in vivo bioorthogonal reactions, or developing new chemical probes that can access new…”